Falk S, Seipelt G, Ganser A, Ottmann O G, Hoelzer D, Stutte H J, Hübner K
Department of Pathology, University of Frankfurt, Germany.
Am J Clin Pathol. 1991 Mar;95(3):355-62. doi: 10.1093/ajcp/95.3.355.
In a phase I/II study, bone marrow biopsy specimens and aspirates of 20 patients with malignant tumors but normal bone marrow (n = 6), bone marrow failure resulting from chemotherapy (n = 4), myelodysplastic syndrome (n = 5), and aplastic anemia (n = 5) were evaluated before and after patients were treated with recombinant human interleukin-3 (rhIL-3). This cytokine proved to be an effective hematopoietic growth factor with only mild side effects. The rhIL-3 treatment led to increased overall bone marrow cellularity with trilinear stimulation of hematopoietic cells, except in most patients with aplastic anemia. In all patients, significant eosinophilia and, in some instances, bone marrow fibrosis developed. In addition to the increase in the number of circulating neutrophilic granulocytes, platelets, and reticulocytes, an increase of peripheral blood monocytes and lymphocytes was observed. The histologic and cytologic findings support the concept that rhIL-3 stimulates the proliferation and differentiation of pluripotent hematopoietic progenitor cells. It appears to be a safe and efficient therapeutic modality in patients with bone marrow failure. Additional clinical studies are needed to determine which patients will profit most from rhIL-3 treatment.
在一项I/II期研究中，对20例患有恶性肿瘤但骨髓正常（n = 6）、化疗导致的骨髓衰竭（n = 4）、骨髓增生异常综合征（n = 5）和再生障碍性贫血（n = 5）的患者，在接受重组人白细胞介素-3（rhIL-3）治疗前后进行了骨髓活检标本和骨髓穿刺液评估。这种细胞因子被证明是一种有效的造血生长因子，副作用轻微。rhIL-3治疗导致总体骨髓细胞增多，造血细胞呈三系刺激，除了大多数再生障碍性贫血患者。在所有患者中，均出现明显的嗜酸性粒细胞增多，在某些情况下还出现骨髓纤维化。除了循环中性粒细胞、血小板和网织红细胞数量增加外，还观察到外周血单核细胞和淋巴细胞增多。组织学和细胞学结果支持rhIL-3刺激多能造血祖细胞增殖和分化的概念。它似乎是骨髓衰竭患者一种安全有效的治疗方式。需要更多的临床研究来确定哪些患者将从rhIL-3治疗中获益最大。
